Selective reduction of graft-versus-host disease-mediating human T cells by ex vivo treatment with soluble Fas ligand

Journal of Immunology

Volumn 183, Issue 1, 2009, Pages 696-705

  Bohana Kashtan, Osnat ^a   Morisot, Sebastien ^a   Hildreth, Richard ^a   Brayton, Cory ^a   Levitsky, Hyam I ^a   Civin, Curt I ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; FAS LIGAND; GAMMA INTERFERON; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; TRANSCRIPTION FACTOR FOXP3;

ALLOIMMUNITY; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CD25+ T LYMPHOCYTE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELL TRANSPLANTATION; CONTROLLED STUDY; EX VIVO STUDY; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE; UPREGULATION; XENOGRAFT; ANIMAL; CELL CULTURE; CYTOLOGY; FEMALE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; METHODOLOGY; MIXED LYMPHOCYTE CULTURE; MOUSE MUTANT; NONOBESE DIABETIC MOUSE; PATHOLOGY; SOLUBILITY; T LYMPHOCYTE SUBPOPULATION; TRANSGENIC MOUSE;

ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; FAS LIGAND PROTEIN; FEMALE; GRAFT VS HOST DISEASE; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; MICE, TRANSGENIC; SOLUBILITY; T-LYMPHOCYTE SUBSETS;

EID: 68949086608     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0800561     Document Type: Article

References (59)

1. Couriel, D., H. Caldera, R. Champlin, and K. Komanduri. 2004. Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management. Cancer 101: 1936-1946.
2. Ferrara, J. L., and P. Reddy. 2006. Pathophysiology of graft-versus-host disease. Semin. Hematol. 43: 3-10.
3. Welniak, L. A., B. R. Blazar, and W. J. Murphy. 2007. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu. Rev. Immunol. 25: 139-170. (Pubitemid 46697905)
4. Ho, V. T., and R. J. Soiffer. 2001. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 98: 3192-3204.
5. - memory T cells without graft-versus-host disease. Blood 103: 1534-1541.
6. + T cells by virtue of their receptor β loci sequences. Proc. Natl. Acad. Sci. USA 100: 1180-1184.
7. + T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biol. Blood Marrow Transplant. 8: 625-632.
8. Datta, A. R., A. J. Barrett, Y. Z. Jiang, A. Guimaraes, D. A. Mavroudis, F. van Rhee, A. A. Gordon, and A. Madrigal. 1994. Distinct T cell populations distinguish chronic myeloid leukemia cells from lymphocytes in the same individual: a model for separating GVHD from GVL reactions. Bone Marrow Transplant. 14: 517-524.
9. Marijt, W. A., M. H. Heemskerk, F. M. Kloosterboer, E. Goulmy, M. G. Kester, M. A. van der Hoorn, S. A. van Luxemburg-Heys, M. Hoogeboom, T. Mutis, J. W. Drijfhout, et al. 2003. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc. Natl. Acad. Sci. USA 100: 2742-2747.
10. Molldrem, J. J., P. P. Lee, C. Wang, K. Felio, H. M. Kantarjian, R. E. Champlin, and M. M. Davis. 2000. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat. Med. 6: 1018-1023.
11. Morita, Y., Y. Heike, M. Kawakami, O. Miura, S. Nakatsuka, M. Ebisawa, S. Mori, R. Tanosaki, T. Fukuda, S. W. Kim, et al. 2006. Monitoring of WT1-specific cytotoxic T lymphocytes after allogeneic hematopoietic stem cell transplantation. Int. J. Cancer 119: 1360-1367.
12. Amrolia, P. J., G. Muccioli-Casadei, H. Huls, S. Adams, A. Durett, A. Gee, E. Yvon, H. Weiss, M. Cobbold, H. B. Gaspar, et al. 2006. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood 108: 1797-1808.
13. Andre-Schmutz, I., F. Le Deist, S. Hacein-Bey-Abina, E. Vitetta, J. Schindler, G. Chedeville, E. Vilmer, A. Fischer, and M. Cavazzana-Calvo. 2002. Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study. Lancet 360: 130-137.
14. Cavazzana-Calvo, M., C. Fromont, F. Le Deist, M. Lusardi, L. Coulombel, J. M. Derocq, I. Gerota, C. Griscelli, and A. Fischer. 1990. Specific elimination of alloreactive T cells by an anti-interleukin-2 receptor B chain-specific immunotoxin. Transplantation 50: 1-7.
15. Fehse, B., O. Frerk, M. Goldmann, M. Bulduk, and A. R. Zander. 2000. Efficient depletion of alloreactive donor T lymphocytes based on expression of two activation-induced antigens (CD25 and CD69). Br. J. Haematol. 109: 644-651.
16. Garderet, L., V. Snell, D. Przepiorka, T. Schenk, J. G. Lu, F. Marini, E. Gluckman, M. Andreeff, and R. E. Champlin. 1999. Effective depletion of alloreactive lymphocytes from peripheral blood mononuclear cell preparations. Transplantation 67: 124-130.
17. Koh, M. B., H. G. Prentice, and M. W. Lowdell. 1999. Selective removal of alloreactive cells from haematopoietic stem cell grafts: graft engineering for GVHD prophylaxis. Bone Marrow Transplant. 23: 1071-1079.
18. Montagna, D., E. Yvon, V. Calcaterra, P. Comoli, F. Locatelli, R. Maccario, A. Fisher, and M. Cavazzana-Calvo. 1999. Depletion of alloreactive T cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity. Blood 93: 3550-3557.
19. Van Dijk, A. M., F. L. Kessler, S. A. Stadhouders-Keet, L. F. Verdonck, G. C. de Gast, and H. G. Otten. 1999. Selective depletion of major and minor histocompatibility antigen reactive T cells: towards prevention of acute graft-versus-host disease. Br. J. Haematol. 107: 169-175.
20. Wehler, T. C., M. Nonn, B. Brandt, C. M. Britten, M. Grone, M. Todorova, I. Link, S. A. Khan, R. G. Meyer, C. Huber, et al. 2007. Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines. Blood 109: 365-373.
21. - allodepletion allows selective elimination of alloreactive human T cells without loss of virus-specific and leukemia-specific effectors. Biol. Blood Marrow Transplant. 14: 518-530.
22. Godfrey, W. R., M. R. Krampf, P. A. Taylor, and B. R. Blazar. 2004. Ex vivo depletion of alloreactive cells based on CFSE dye dilution, activation antigen selection, and dendritic cell stimulation. Blood 103: 1158-1165.
23. Chen, B. J., X. Cui, C. Liu, and N. J. Chao. 2002. Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process. Blood 99: 3083-3088.
24. Georgantas, R. W., III, O. Bohana-Kashtan, and C. I. Civin. 2006. Ex vivo soluble fas ligand treatment of donor cells to selectively reduce murine acute graft versus host disease. Transplantation 82: 471-478.
25. Hartwig, U. F., M. Robbers, C. Wickenhauser, and C. Huber. 2002. Murine acute graft-versus-host disease can be prevented by depletion of alloreactive T lymphocytes using activation-induced cell death. Blood 99: 3041-3049.
26. Hartwig, U. F., M. Nonn, S. Khan, I. Link, C. Huber, and W. Herr. 2008. Depletion of alloreactive donor T lymphocytes by CD95-mediated activation-induced cell death retains antileukemic, antiviral, and immunoregulatory T cell immunity. Biol. Blood Marrow Transplant. 14: 99-109.
27. c (null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 100: 3175-3182.
28. Shultz, L. D., B. L. Lyons, L. M. Burzenski, B. Gott, X. Chen, S. Chaleff, M. Kotb, S. D. Gillies, M. King, J. Mangada, et al. 2005. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2Rγ null mice engrafted with mobilized human hemopoietic stem cells. J. Immunol. 174: 6477-6489.
29. -/- double-mutant mice. Blood 102: 2522-2531.
30. + T cells by a flow cytometric assay for degranulation. J. Immunol. Methods 281: 65-78.
31. + cells recognizing HER2/neu vaccine peptides. Breast Cancer Res. Treat. 92: 85-93.
32. Aktas, E., U. C. Kucuksezer, S. Bilgic, G. Erten, and G. Deniz. 2009. Relationship between CD107a expression and cytotoxic activity. Cell. Immunol. 254: 149-154.
33. + T regulatory cells in humans. Hum. Immunol. 66: 13-20.
34. Gavin, M. A., T. R. Torgerson, E. Houston, P. DeRoos, W. Y. Ho, A. Stray-Pedersen, E. L. Ocheltree, P. D. Greenberg, H. D. Ochs, and A. Y. Rudensky. 2006. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc. Natl. Acad. Sci. USA 103: 6659-6664.
35. + T cells. Eur. J. Immunol. 37: 129-138.
36. + T cells in vitro and in vivo. Transplantation 69: 605-609.
37. Ridgway, W., M. Fasso, and C. G. Fathman. 1998. Following antigen challenge, T cells up-regulate cell surface expression of CD4 in vitro and in vivo. J. Immunol. 161: 714-720. (Pubitemid 28323534)
38. Martins, S. L., L. S. St John, R. E. Champlin, E. D. Wieder, J. McMannis, J. J. Molldrem, and K. V. Komanduri. 2004. Functional assessment and specific depletion of alloreactive human T cells using flow cytometry. Blood 104: 3429-3436.
39. + immunoregulatory T cells: new therapeutics for graft-versus-host disease. J. Exp. Med. 196: 401-406.
40. + regulatory T cells protects from lethal acute GVHD. Blood 105: 2220-2226.
41. + regulatory T cells suppress lethal acute graft-versushost disease after allogeneic bone marrow transplantation. J. Exp. Med. 196: 389-399.
42. + immune regulatory cells inhibits graft-versus-host disease lethality. Blood 99: 3493-3499.
43. + immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J. Exp. Med. 193: 1311-1318.
44. + regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat. Med. 9: 1144-1150.
45. Jones, S. C., G. F. Murphy, and R. Korngold. 2003. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response. Biol. Blood Marrow Transplant. 9: 243-256.
46. + regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J. Clin. Invest. 112: 1688-1696.
47. Rezvani, K., S. Mielke, M. Ahmadzadeh, Y. Kilical, B. N. Savani, J. Zeilah, K. Keyvanfar, A. Montero, N. Hensel, R. Kurlander, and A. J. Barrett. 2006. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 108: 1291-1297.
48. + T cells promote engraftment and tolerance following MHC-mismatched hematopoietic cell transplantation. Blood 105: 1828-1836.
49. Banz, A., C. Pontoux, and M. Papiernik. 2002. Modulation of Fas-dependent apoptosis: a dynamic process controlling both the persistence and death of CD4 regulatory T cells and effector T cells. J. Immunol. 169: 750-757.
50. Papiernik, M., M. do Carmo Leite-de-Moraes, C. Pontoux, A. M. Joret, B. Rocha, C. Penit, and M. Dy. 1997. T cell deletion induced by chronic infection with mouse mammary tumor virus spares a CD25-positive, IL-10-producing T cell population with infectious capacity. J. Immunol. 158: 4642-4653.
51. + regulatory T cells are highly susceptible to CD95 ligand-but not to TCR-mediated cell death. J. Immunol. 175: 32-36.
52. Bonini, C., G. Ferrari, S. Verzeletti, P. Servida, E. Zappone, L. Ruggieri, M. Ponzoni, S. Rossini, F. Mavilio, C. Traversari, and C. Bordignon. 1997. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276: 1719-1724.
53. Pachnio, A., S. Dietrich, W. Klapper, A. Humpe, M. Schwake, R. Sedlacek, M. Gramatzki, and C. Beck. 2006. Proliferation-based T-cell selection for immunotherapy and graft-versus-host-disease prophylaxis in the context of bone marrow transplantation. Bone Marrow Transplant. 38: 157-167.
54. + splenic dendritic cells. Blood 103: 2668-2676.
55. Givan, A. L., J. L. Fisher, M. G. Waugh, N. Bercovici, and P. K. Wallace. 2004. Use of cell-tracking dyes to determine proliferation precursor frequencies of antigen-specific T cells. In Flow Cytometry Protocols, 2nd Ed. T. S. Hawley and R. G. Hawley, eds. Human Press, Totowa, pp. 109-124.
56. Solomon, S. R., S. Mielke, B. N. Savani, A. Montero, L. Wisch, R. Childs, N. Hensel, J. Schindler, V. Ghetie, S. F. Leitman, et al. 2005. Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood 106: 1123-1129.
57. + T cell-mediated graft-versus-host disease model. J. Clin. Invest. 112: 1880-1886.
58. Cathcart, K., J. Pinilla-Ibarz, T. Korontsvit, J. Schwartz, V. Zakhaleva, E. B. Papadopoulos, and D. A. Scheinberg. 2004. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 103: 1037-1042.
59. Falkenburg, J. H., A. R. Wafelman, P. Joosten, W. M. Smit, C. A. van Bergen, R. Bongaerts, E. Lurvink, M. van der Hoorn, P. Kluck, J. E. Landegent, et al. 1999. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood 94: 1201-1208.